# Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

> **NCT02509312** · PHASE4 · COMPLETED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 70 (actual)

## Conditions studied

- Analgesia, Obstetrical
- Postpartum Hemorrhage
- Opioid Use
- Nonsteroidals (NSAIDs)Toxicity
- Coagulation Defect; Postpartum
- Postoperative Pain
- Ketorolac Adverse Reaction
- Blood Loss, Postoperative

## Interventions

- **DRUG:** Ketorolac
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02509312
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509312, "Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02509312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*